El Salvador, Guatemala, Honduras II treatment protocol: continuation therapy for standard-risk acute lymphocytic leukemia (ALL).
| Weeks 1-3 | Methotrexate | 40 mg/m2 IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Week 4 | Dexamethasone | 8 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 5 | Methotrexate | 40 mg/m2 IM |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Vincristine | 1.5 mg/m2 IV | |
| Week 6 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Weeks 7-11 | Repeat induction and consolidation | |
| Weeks 12-14 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 15 | Methotrexate | 2 g/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Weeks 16-18 | Methotrexate | 40 mg/m2 IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 19 | Dexamethasone | 8 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 20 | Methotrexate | 40 mg/m2 IV/IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Vincristine | 1.5 mg/m2 IV | |
| Weeks 21-23 | Methotrexate | 40 mg/m2 IV/IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 24 | Methotrexate | 2 g/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Chemotherapy schedule given between weeks 16 and 24 is repeated during the first year (a total of six doses of high-dose methotrexate are administered during continuation) | ||
| Triple IT given on weeks 1, 2, 3, 7, 10, 12, 15, 24, 31, 36, 39, 43, 47, 55 | ||
| Dexamethasone and vincristine stop after week 100 | ||
| Continuation therapy extended 3 years for boys | ||
| Weeks 1-3 | Methotrexate | 40 mg/m2 IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Week 4 | Dexamethasone | 8 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 5 | Methotrexate | 40 mg/m2 IM |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Vincristine | 1.5 mg/m2 IV | |
| Week 6 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Weeks 7-11 | Repeat induction and consolidation | |
| Weeks 12-14 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 15 | Methotrexate | 2 g/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Weeks 16-18 | Methotrexate | 40 mg/m2 IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 19 | Dexamethasone | 8 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 20 | Methotrexate | 40 mg/m2 IV/IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Vincristine | 1.5 mg/m2 IV | |
| Weeks 21-23 | Methotrexate | 40 mg/m2 IV/IM weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 24 | Methotrexate | 2 g/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Chemotherapy schedule given between weeks 16 and 24 is repeated during the first year (a total of six doses of high-dose methotrexate are administered during continuation) | ||
| Triple IT given on weeks 1, 2, 3, 7, 10, 12, 15, 24, 31, 36, 39, 43, 47, 55 | ||
| Dexamethasone and vincristine stop after week 100 | ||
| Continuation therapy extended 3 years for boys | ||